• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications.

作者信息

Tsai Yi-Hsuan, OjiNjideka Hemphill Nefertiti, Kurth Tobias

机构信息

Department of Family Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Harvard T. H. Chan School of Public Health, Boston, MA, USA.

出版信息

Diabetologia. 2025 Jan;68(1):247-248. doi: 10.1007/s00125-024-06300-7. Epub 2024 Oct 30.

DOI:10.1007/s00125-024-06300-7
PMID:39476020
Abstract
摘要

相似文献

1
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications.探讨评估钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂对糖尿病眼部并发症风险影响时的方法学考量。
Diabetologia. 2025 Jan;68(1):247-248. doi: 10.1007/s00125-024-06300-7. Epub 2024 Oct 30.
2
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂治疗 2 型糖尿病的糖尿病视网膜病变和糖尿病黄斑水肿风险：来自全球联合数据库的真实世界数据研究。
Diabetologia. 2024 Jul;67(7):1271-1282. doi: 10.1007/s00125-024-06132-5. Epub 2024 Apr 8.
3
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.在台湾，衰弱对 2 型糖尿病患者 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响：一项回顾性、全国性、纵向研究。
Lancet Healthy Longev. 2024 Sep;5(9):100621. doi: 10.1016/j.lanhl.2024.07.004. Epub 2024 Sep 13.
4
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.解决评估SGLT2抑制剂和GLP-1受体激动剂对糖尿病眼部并发症影响中的方法学考量。对Tsai Y-H、Hemphill NO、Kurth T的回复
Diabetologia. 2025 Jan;68(1):249-250. doi: 10.1007/s00125-024-06314-1. Epub 2024 Nov 7.
5
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.GLP-1 激动剂和 SGLT-2 抑制剂对糖尿病视网膜病变进展的影响：一项汇总电子健康记录数据研究。
Am J Ophthalmol. 2024 Sep;265:39-47. doi: 10.1016/j.ajo.2024.04.010. Epub 2024 Apr 17.
6
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.GLP-1 激动剂和 SGLT2 抑制剂在妊娠和哺乳期对后代结局的影响：证据的系统评价。
Front Endocrinol (Lausanne). 2023 Oct 10;14:1215356. doi: 10.3389/fendo.2023.1215356. eCollection 2023.
7
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.2型糖尿病的精准医学：对胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂治疗效果异质性的系统评价
medRxiv. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868.
8
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.使用胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病后的治疗效果异质性：一项系统评价
Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w.
9
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.SGLT2 抑制剂、GLP-1 受体激动剂、DPP-4 抑制剂和磺脲类药物对主要不良心血管事件风险的比较效果：使用电子健康记录模拟随机目标试验。
Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. doi: 10.1016/S2213-8587(23)00171-7. Epub 2023 Jul 24.
10
Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.在台湾 2 型糖尿病患者中，钠-葡萄糖共转运蛋白-2 抑制剂与糖尿病性黄斑水肿的风险：一项多机构队列研究。
Diabetes Obes Metab. 2021 Sep;23(9):2067-2076. doi: 10.1111/dom.14445. Epub 2021 Jun 9.

引用本文的文献

1
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.解决评估SGLT2抑制剂和GLP-1受体激动剂对糖尿病眼部并发症影响中的方法学考量。对Tsai Y-H、Hemphill NO、Kurth T的回复
Diabetologia. 2025 Jan;68(1):249-250. doi: 10.1007/s00125-024-06314-1. Epub 2024 Nov 7.

本文引用的文献

1
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.SGLT2 抑制剂在英国 2 型糖尿病且年龄超过 70 岁人群中的安全性和有效性：一种工具变量法。
Diabetologia. 2024 Sep;67(9):1817-1827. doi: 10.1007/s00125-024-06190-9. Epub 2024 Jun 5.
2
Doubly Robust Causal Modeling to Evaluate Device Implantation.用于评估设备植入的双重稳健因果模型
JAMA Intern Med. 2024 Jul 1;184(7):834-835. doi: 10.1001/jamainternmed.2024.1181.
3
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
胰高血糖素样肽 1 受体激动剂的使用与甲状腺癌风险：斯堪的纳维亚队列研究。
BMJ. 2024 Apr 10;385:e078225. doi: 10.1136/bmj-2023-078225.
4
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂治疗 2 型糖尿病的糖尿病视网膜病变和糖尿病黄斑水肿风险：来自全球联合数据库的真实世界数据研究。
Diabetologia. 2024 Jul;67(7):1271-1282. doi: 10.1007/s00125-024-06132-5. Epub 2024 Apr 8.
5
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.胰高血糖素样肽-1受体激动剂与甲状腺癌风险
Diabetes Care. 2023 Feb 1;46(2):384-390. doi: 10.2337/dc22-1148.
6
Effect of ICD-9 to ICD-10 Transition on Accuracy of Codes for Stage of Diabetic Retinopathy and Related Complications: Results from the CODER Study.ICD-9 到 ICD-10 转换对糖尿病视网膜病变及其相关并发症分期编码准确性的影响：来自 CODER 研究的结果。
Ophthalmol Retina. 2021 Apr;5(4):374-380. doi: 10.1016/j.oret.2020.08.004. Epub 2020 Aug 15.
7
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.